Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of RLAY is 15 and suggests 62% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell